Trade Desk Expands Pharma Measurement Capabilities, but Core Growth Challenges Persist

What happened

Trade Desk's Q2 2026 revenue rose only 3% year over year to $715.1 million, with existing-client gross spend declining, a sharp slowdown from FY25's 18% growth. The company now announces integrations with Veeva Crossix and IQVIA, giving pharmaceutical advertisers more granular measurement and optimization tools on its platform. While healthcare is a large and high-value advertising vertical, this expansion does not directly address the agency trust disputes and Kokai workflow friction that have suppressed spending from existing clients. Management guided Q3 2026 revenue to at least $650 million, suggesting continued modest growth, and the stock trades at 9.8x EV/EBITDA after an 80% drawdown from 2025 highs. The pharma integrations may open a new revenue stream, but proof of stabilization in core client spend remains the critical near-term catalyst.

Implication

Pharma advertisers represent a potentially lucrative vertical given high regulatory and measurement requirements, and these integrations could help Trade Desk win incremental budgets over time. However, the core problems of agency concentration (two holding companies were 30% of 2025 gross billings) and Kokai migration friction have not been resolved by this announcement. Until the company shows two consecutive quarters of positive existing-client spend growth and revenue re-acceleration above 10%, the recovery thesis remains unproven. A better entry point may exist below $15, or after a quarter where Q3 results exceed guidance with evidence of improving client retention and spend velocity. Investors should treat the pharma news as a minor tailwind rather than a fundamental shift in the turnaround narrative.

Thesis delta

The current WAIT rating and thesis remain essentially unchanged. The pharma integrations add a new potential growth avenue but do not address the existing-client spend declines or agency trust issues that have driven the slowdown. We need evidence of spend stabilization and workflow repair before upgrading the thesis.